Qlife Holding AB, Interim report Q3 2022
Rights issue and targeted focus on CRP-assay readinessFinancial summary – third quarter 2022 · Revenue in the period amounted to kSEK 1,967 (5,871). Revenue includes sales ofEgoo.Health devices and capsules for the device. Continued decline in test activity following the end of Covid travel restrictions has led to a decline in revenue in line with our expectations. · EBITDA for the period amounted to kSEK -14,850 (-12,146), and net loss kSEK -20,678 (-12,268). · The total cash flow in the third quarter amounted to kSEK -21,766 (-25,580). · Earnings per share before/after